FDA approves landmark pancreatic cancer drug that’s shown to improve survival
Tap title to read story
The Food and Drug Administration approved Rasonque (daraxonrasib) on August 26, 2026, marking the first targeted RAS-inhibitor therapy cleared for advanced pancreatic cancer. Manufactured by Revolution Medicines, the once-daily oral tablet is indicated for adults with metastatic pancreatic adenocarcinoma who previously received systemic therapy or cannot tolerate multi-agent chemotherapy. Approval was granted more than six months ahead of the agency's user fee deadline under Priority Review and National Priority Voucher pilot programs. In a 500-patient Phase 3 clinical trial, patients taking daraxonrasib achieved a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy. Common adverse events included skin rash, diarrhea, stomatitis, nausea, and fatigue. Oncologists view the decision as a major advancement against a malignancy causing over 52,000 U.S. deaths annually, though experts emphasize the drug is a management therapy rather than a cure.
More context
Timeline
- On April 13 2026 Phase 3 RASolute 302 trial trial met endpoints.
- On May 31 2026 trial results presented at ASCO annual meeting.
- On May 31 2026 FDA granted expanded access protocol for patients.
- On July 07 2026 EMA began expedited review of daraxonrasib.
- On July 22 2026 Revolution Medicines formally submitted NDA to FDA.
- On August 26 2026 FDA officially approved Rasonque six months early.
- On August 26 2026 Revolution Medicines scheduled commercial presentation webcast.
- By September 2026 initial commercial prescription shipments begin nationwide.
- By late 2026 European regulators issue regional marketing authorization decision.
- By 2027 clinical trials evaluate daraxonrasib in first-line combination therapies.
Why it matters
Immediate US impact: Patients gain immediate access to first-in-class targeted oral therapy. Possible long-term US impact: Validates RAS-targeted drug development platform across multiple solid tumors. Most affected groups: Metastatic pancreatic adenocarcinoma patients, oncologists, Revolution Medicines investors, caregivers. What readers should prioritize: Verify treatment eligibility criteria with qualified medical oncology providers.
Coverage notes
Left: Highlights regulatory speed under public health initiatives expanding patient access. Center: Focuses on clinical trial survival statistics, safety, and approval. Right: Highlights innovation by private drugmakers and expedited regulatory flexibility.
Primary report
publication_date: August 26, 2026 trigger_description: FDA approved Rasonque tablets for pancreatic cancer on August 26.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
